Future Directions in the Management of Endometrial Cancer

EP: 1.Patient Case: A 64-Year-Old Woman With Recurrent Endometrial Cancer

EP: 2.Endometrial Cancer: Factors in Selecting First- and Second-Line Therapy

EP: 3.Immune Checkpoint Inhibitors in Recurrent Endometrial Cancer: Clinical Trial Data

EP: 4.Recurrent Endometrial Cancer: An Evolving Treatment Landscape

EP: 5.Combination IO Strategies in Advanced Endometrial Cancer: RUBY and GY018

EP: 6.Single-Agent IO Therapy in Advanced Endometrial Cancer: PHAEDRA and DOMENICA

EP: 7.Adjuvant IO Strategies in Endometrial Cancer: RAINBO and GY020

EP: 8.Antibody Drug Conjugate Data in Endometrial Cancer: TROPiCS-03

Now Viewing

EP: 9.Future Directions in the Management of Endometrial Cancer

Transcript:

Ritu Salani, MD, MBA: Future directions and unmet needs in treating mismatch repair deficient endometrial cancer are still important. As we move checkpoint inhibitors to the frontline setting, either in early-stage in conjunction with radiation therapy or in the frontline setting with chemotherapy, the role of IO [immunotherapy] after IO is going to be explored as we're going to have patients who do recur, and understanding the impact of moving our second-line therapies into frontline setting will continue to be challenging. This also opens the door for other agents to be explored. We mentioned Sassy, which is an ADC [antibody drug conjugate] turning Trop-2, which may play a role. There's also some exciting data emerging about the HER2 ADC. We're also seeing other options such as maintenance therapy with selinexor in endometrial cancer. I hope that these unmet needs that we're continuing to create by moving therapies earlier will be addressed and we have some exciting trials on the horizon. The most important takeaway is that immunotherapy is impactful. We saw this with PARP inhibitors in the ovarian cancer setting. Now, what we're seeing is the mismatch repair deficient population is truly having a remarkable benefit from the addition of checkpoint inhibitors to chemotherapy in the frontline setting. This should be a standard of care. We're waiting for FDA approval, which should happen in the near future. This is really game-changing and I'm hoping will cure many patients that we were unable to cure before. The data is still out on that but I think this is a really impactful addition to chemotherapy, and we may have multiple options with dostarlimab and pembrolizumab. I think the other takeaway is that these patients as they recur will continue to need better options. Looking at clinical trials, which there are many right now, will continue to offer our patients the best options, and hopefully continue to change the standard of care for these patients.

Transcript edited for clarity.